Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study
Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study
复制标题
DOI：
10.2478/rjim-2020-0013
复制
发表时间：
2020-09-01
影响因子：
1.9
通讯作者：
Ebrahimpour, Soheil
中科院分区：
文献类型：
--
作者：
Javanian, Mostafa;Bayani, Masomeh;Ebrahimpour, Soheil
背景于二零一九年十二月，中国爆发新型冠状病毒病（COVID-19）。冠状病毒现在已经蔓延到所有大陆。通过对2019冠状病毒病的临床特征、实验室检查结果的分析，为该病毒的研究提供参考。我们对一系列100名确诊的COVID-19患者的临床症状和实验室检查结果进行了回顾性队列研究。这些患者于2020年2月25日至2020年3月12日入住Babol医科大学附属医院（Ayatollah Rohani，Shahid Beheshti和Yahyanejad医院）。19例患者在住院期间死亡，81例患者出院。非存活患者的C-反应蛋白（CRP）显著升高（MD：46.37，95% CI：20.84，71.90; P = 0.001），白色血细胞（WBC）（MD：3.10，95%CI：1.53，4.67; P < 0.001）（MD：-8.75，95%CI：-12.62，-4.87; P < 0.001）与存活患者相比数据分析显示共病情况（aRR：2.99，95%CI：1.09，8.21，P = 0.034）、高CRP水平（aRR：1.02，95%CI：1.01，1.03，P = 0.044）和低淋巴细胞计数（aRR：0.82，95%CI：0.73，0.93，P = 0.003）与死亡风险增加相关。根据我们的研究结果，大多数非幸存者是患有合并症的老年人。淋巴细胞减少和白细胞水平升高沿着CRP升高与死亡风险增加相关。因此，最好在COVID-19患者治疗期间定期评估这些标志物。
Background. In December 2019, China has experienced an outbreak of novel coronavirus disease 2019 (COVID-19). Coronavirus has now spread to all of the continents. We aimed to consider clinical characteristics, laboratory data of COVID-19 that provided more information for the research of this novel virus.Methods. We performed a retrospective cohort study on the clinical symptoms and laboratory findings of a series of the 100 confirmed patients with COVID-19. These patients were admitted to the hospitals affiliated to Babol University of Medical Sciences (Ayatollah Rohani, Shahid Beheshti and Yahyanejad hospitals) form 25 February 2020 to 12 March 2020.Results. Nineteen patients died during hospitalization and 81 were discharged. Non-survivor patients had a significantly higher C-reactive protein (CRP) (MD: 46.37, 95% CI: 20.84, 71.90; P = 0.001), white blood cells (WBCs) (MD: 3.10, 95% CI: 1.53, 4.67; P < 0.001) and lower lymphocyte (MD: -8.75, 95% CI: -12.62, -4.87; P < 0.001) compared to survivor patients Data analysis showed that comorbid conditions (aRR: 2.99, 95% CI: 1.09, 8.21, P = 0.034), higher CRP levels (aRR: 1.02, 95% CI: 1.01, 1.03, P = 0.044), and lower lymphocyte (aRR: 0.82, 95% CI: 0.73, 0.93, P = 0.003) were associated with increased risk of death.Conclusions. Based on our findings, most non-survivors are elderly with comorbidities. Lymphopenia and increased levels of WBCs along with elevated CRP were associated with increased risk of death. Therefore, it is best to be regularly assessed these markers during treatment of COVID-19 patients.